First UK ‘Promising Innovative Medicine’ designation awarded
Dec 15, 2014
An innovative cell therapy for cancer has become the first designated ‘promising’ as part of a scheme to get medicines to patients quicker.
The medicine, named DCVax-L, has been developed by US-based pharmaceutical company Northwest Biotherapeutics Inc (NW Bio) and is the first drug to be awarded the UK’s new ‘Promising Innovative Medicine’ (PIM) designation. The designation is the initial step in the Early Access to Medicines Scheme (EAMS) which aims to increase patient access to medicines where there is an unmet medical need.
Press article here.